Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 9/20 | 0.42 |
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753536 | 1.00 | DRD3 (0.44) | DRD3NPC1RAB9AMRGPRX4HTT | |
| SCHEMBL4751931 | 0.92 | HCRTR1 (0.38) | DRD3NPC1RAB9AHTTNPSR1 | |
| SCHEMBL4294633 | 0.92 | HCRTR1 (0.38) | DRD3NPC1RAB9AHTTNPSR1 | |
| Hydrochloric Acid SCHEMBL4285557 | 0.88 | FFAR1 (0.36) | NPC1RAB9ANPSR1KDM4EHPGD | |
| SCHEMBL4292951 | 0.88 | KDM4E (0.43) | RAB9AMRGPRX4HTTNPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL4285448 | 0.87 | CPS1 (0.40) | — | |
| SCHEMBL4281738 | 0.87 | REN (0.37) | HTTKDM4EHPGD | |
| SCHEMBL4752327 | 0.87 | REN (0.37) | HTTKDM4EHPGD | |
| SCHEMBL8117540 | 0.86 | MRGPRX4 (0.44) | DRD3NPC1RAB9AMRGPRX4 | |
| SCHEMBL4281811 | 0.84 | PTGES (0.42) | NPC1RAB9AHTTNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | DRD3 3476/4885NPC1 1165/4885RAB9A 1247/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | DRD3 3476/4885NPC1 1165/4885RAB9A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.